dc.contributor
Institut Català de la Salut
dc.contributor
[Coll-Martinez C, Salavedra-Pont J, González-del-Rio M, Álvarez-Bravo, G] Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Santa Caterina Hospital, Salt, Girona, Spain. Neurodegeneration and Neuroimflammation Research Group, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, Spain. [Quintana E] Neurodegeneration and Neuroimflammation Research Group, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, Spain. Medical Sciences Department, University of Girona, Girona, Spain. REEM, Multiple Sclerosis Spanish Network, Instituo de Salud Carlos III, Madrid, Spain. [Buxó M] Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, Spain. [Gómez I, Muñoz-San Martín, M] Neurodegeneration and Neuroimflammation Research Group, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, Spain. [Villar LM] REEM, Multiple Sclerosis Spanish Network, Instituto de Salud Carlos III, Madrid, Spain. Immunology Department, Ramon y Cajal University Hospital, IRYCIS, Madrid, Spain. [Robles-Cedeño R, Ramió-Torrentà Ll] Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Neurodegeneration and Neuroimflammation Research Group, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, Spain. Medical Sciences Department, University of Girona, Girona, Spain. REEM, Multiple Sclerosis Spanish Network, Instituo de Salud Carlos III, Madrid, Spain. [Gich J] Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. Neurodegeneration and Neuroimflammation Research Group, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, Spain. Medical Sciences Department, University of Girona, Girona, Spain
dc.contributor
Hospital Universitari de Girona Dr Josep Trueta
dc.contributor.author
Coll-Martinez, Clàudia
dc.contributor.author
Quintana, Ester
dc.contributor.author
Salavedra Pont, Judit
dc.contributor.author
Buxó, Maria
dc.contributor.author
González del Rio, Marina
dc.contributor.author
Gómez Aguilar, Immaculada
dc.contributor.author
Muñoz San Martín, María
dc.contributor.author
Álvarez Bravo, Gary
dc.contributor.author
Robles-Cedeño, René
dc.contributor.author
Gich, Jordi
dc.contributor.author
Villar, Luisa M
dc.contributor.author
Ramió-Torrentà, Lluís
dc.date.accessioned
2025-10-24T10:56:07Z
dc.date.available
2025-10-24T10:56:07Z
dc.date.issued
2023-03-16T10:50:12Z
dc.date.issued
2023-03-16T10:50:12Z
dc.identifier
Coll-Martinez C, Quintana E, Salavedra-Pont J, Buxó M, González-del-Rio M, Gómez I, et al. Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis. Brain Behav. 2021 Dec; 11(12):e2405.
dc.identifier
https://hdl.handle.net/11351/9182
dc.identifier
10.1002/brb3.2405
dc.identifier.uri
https://hdl.handle.net/11351/9182
dc.description.abstract
Bandes oligoclonals; Esclerosi múltiple; Disfunció cognitiva
dc.description.abstract
Bandas oligoclonales; Esclerosis múltiple; Disfunción cognitiva
dc.description.abstract
Oligoclonal bands; Multiple sclerosis; Cognitive dysfunction
dc.description.abstract
Background: An association has been found between the presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid and a more severe clinical multiple sclerosis course.
Objective: To investigate lipid-specific oligoclonal IgM bands as a prognostic biomarker of cognitive impairment in the early stages of multiple sclerosis.
Methods: Forty-four patients underwent neuropsychological assessment at baseline and 4 years. Cognitive performance at follow-up was compared adjusting by age, education, anxiety-depression, and baseline performance.
Results: LS-OCMB+ patients only performed worse for Long-Term Storage in the Selective Reminding Test (p = .018).
Conclusion: There are no remarkable cognitive differences between LS-OCMB- and LS-OCMB+ patients in the early stages of MS.
dc.format
application/pdf
dc.relation
Brain and Behavior;11(12)
dc.relation
https://doi.org/10.1002/brb3.2405
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Esclerosi múltiple
dc.subject
Marcadors bioquímics
dc.subject
Trastorns de la cognició
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers::Oligoclonal Bands
dc.subject
DISEASES::Immune System Diseases::Autoimmune Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
dc.subject
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurocognitive Disorders::Cognition Disorders::Cognitive Dysfunction
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores::bandas oligoclonales
dc.subject
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos neurocognitivos::trastornos cognitivos::disfunción cognitiva
dc.subject
ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
dc.title
Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
